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2,3,7,8-Tetrachlorodibenzo-p-dioxin
(TCDD) is an environmental pollutant orig-
inating from the chemical industry or waste
incineration that causes low-level accumula-
tion in the general population via the food
chain (1,2). In the past, TCDD was intro-
duced as a toxic compound to the general
public by industrial accidents, most notably
in Seveso, Italy, in 1976 (3) and at the BASF
trichlorphenol unit in Germany in the 1950s
(4). As in the Seveso incident, where thou-
sands of inhabitants were exposed to
TCDD, no significant health effects or
pathologic laboratory parameters were
reported for humans after 20 years of obser-
vation, except for about 200 chloracne cases
and minimal laboratory effects in the period
of acute exposure (3,5). Similarly, long-term
observations in workers exposed to TCDD
revealed that organs other than the skin were
only marginally affected or not affected in
association with TCDD exposure (4,6,7).
Most of the reports on acute TCDD intoxi-
cation date from decades ago, before assess-
ment of TCDD levels in blood was possible.
Therefore, the severity of TCDD exposure
was classiﬁed solely on the basis of the chlo-
racne status and history (8). In this paper we
report on the clinical course and laboratory
data in two individuals with the highest
TCDD levels ever recorded in adults.
Case Summaries
Patient 1. In March 1998, a 30-year-old
woman was admitted to the Department of
Dermatology of the University of Vienna
Medical School with acute centrofacial
inﬂammation and acne, which had begun in
late autumn 1997 shortly after she had moved
into a new office space at a textile research
institute. Clinically, acne fulminans was sus-
pected, and treatment with high-dose methyl-
prednisolone (1 mg/kg body weight/day) was
initiated. In the following weeks, acute
inﬂammation subsided, but hundreds of cysts
developed not only on the face but also on
sites normally not affected in acne patients,
such as the auricular areas, the eyelids, the
genital region, the limbs, and the trunk.
Based on the course and the conspicuous clin-
ical picture, chloracne was suspected and con-
firmed by the detection of 144,000 pg
TCDD/g blood fat, the highest value ever
recorded in a human (5); this corresponds to
a calculated body burden of 1.6 mg TCDD
and a dosage of 25 µg/kg body weight (9).
The disease progressed continuously; after 1
year, the patient’s whole face was densely
covered with cysts (Figure 1A,B). Until sum-
mer 1998 only few lesions were present on
the body skin (Figure 1C ), but 1 year later
the entire skin surface was covered with
inﬂamed, painful cysts (Figure 1D). As a pos-
sible new skin manifestation observed in
TCDD intoxication, the patient exhibited
palmoplantar keratoderma (10).
Besides the skin disease, the patient had
experienced gastrointestinal symptoms
including nausea, vomiting, epigastric pain,
and loss of appetite since late autumn 1997.
These symptoms had prompted the patient
to follow a medically supervised diet, which
resulted in a weight loss of about 10 kg
within the 4 months before hospital admis-
sion. Over the next year, the patient’s
abdominal symptoms subsided.
Moderately elevated levels of blood lipids,
a normocytic, normochromic anemia, and
leukocytosis were the most prominent patho-
logic changes of the routine laboratory para-
meters. The patient was thrombopenic in the
first 3 months of observation; antiplatelet
antibodies were negative. Histology carried
out in October 1999 revealed a normocellular
bone marrow with prominent myelopoiesis,
but there was no morphologic evidence for
dyshematopoiesis and/or an increased blast
cell count; no chromosomal abnormality was
detectable. Moreover, because immunoglobu-
lin or T-cell receptor rearrangements were not
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row, it was possible to exclude a systemic
clonal lymphoproliferative disease as cause for
the anemia. In vitro culture of hematopoietic
progenitor cells showed normal growth of
myeloid progenitor cells [colony forming
unit-granulocyte/macrophage (CFU-GM)]
and only a slightly decreased formation of ery-
throcyte colonies [burst-forming unit-ery-
throid (BFU-E), 80/100,000 mononuclear
cells (MNC), normal value 128–474/100,000
MNC]. Lymphocyte subset analysis showed a
marginal decrease in the percentage of nat-
ural killer (NK) cells. Several other immuno-
logic parameters (Table 1) were within the
normal range. 
The patient, a mother of two healthy
children, had been taking birth control pills;
menstruation ceased in late autumn 1997,
the presumed time of TCDD intoxication.
Secondary amenorrhoea was still present in
late 2000 after she stopped using hormonal
contraceptives in summer 1999. The hor-
monal status showed slightly decreased
estradiol and progesterone levels and, since
May 1999, a mild elevation of prolactin,
which coincided with the initiation of anti-
depressive therapy (paroxetin; Seroxat:
SmithKline Beecham, Brunn/Gerbirge,
Austria). The measurement of hormone
reserve and regulation by dynamic tests [L-
arginine test (300 mL 10% L-arginine IV
within 30 min: normal increase of growth
hormone), thyrotropin-releasing hormone
test, gonadotropin-releasing hormone test
(Gonadorelin; Relefact LH-RH 0.100 mg; 1
mL as bolus IV; normal increase of follicle-
stimulating hormone and luteinizing hor-
mone), adrenocorticotropic hormone
(ACTH) test (121 µg corticorelin-trifluo-
roacetate IV; normal increase of cortisol,
testosterone, dehydroepiandrosterone-S,
17α -hydroxyprogesterone, and androsten-
dion) (11)] revealed normal results, which
ruled out the possibility of a disturbance of
the hypothalamic–pituitary–target system. 
Investigations such as ultrasound of the
abdomen, chest X ray, pulmonary function
tests, and neurologic, psychodynamic, and
electrophysiologic investigations were unre-
vealing. Gastroscopy in February 1998
showed acute helicobacter-negative gastritis,
corresponding to the epigastric symptoms
reported. 
Patient 1 was treated with isotretinoin
(0.7 mg/kg body weight/day Roaccutan;
Hoffmann-LaRoche, Basel, Switzerland)
beginning in April 1998, but this treatment
was discontinued in December 1998 because
the patient reached cumulative dose of 13 g
and with no observed clinical benefit.
Recurrent deep inﬂammation of cysts repeat-
edly required and still requires surgical inter-
ventions and mechanical removal of the
comedones, oral adminstration of methyl-
prednisolone (4–40 mg/day Urbason;
Hoechst Marion Roussel, Vienna, Austria),
and analgesic drugs and antibiotics. In an
attempt to detoxify the patient, we adminis-
tered olestra, a nonabsorbable, nondigestible
fat-substitute, on a trial basis in autumn 1998
(9), and the patient is still receiving this treat-
ment. TCDD blood levels were measured
before and during the course of the olestra
treatment and are still monitored; the TCDD
concentrations have decreased over time
(30,300 pg/g blood fat in October 2000).
Patient 2. The patient’s colleague, a 27-
year-old woman who worked in the same
room, consulted us in April 1998. She had
developed multiple small cysts on the malar
crescent (Figure 2A) and the auricular areas,
albeit to a much lesser degree than Patient 1.
Also, Patient 2 had been suffering from gas-
trointestinal symptoms from autumn 1997
to early 1998. Her initial TCDD blood
level, measured in June 1998, was 26.000
pg/g blood fat, corresponding to a calculated
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Figure 1. Clinical picture of Patient 1 one year after the diagnosis of chloracne. Multiple cysts were pre-
sent (A) on the face and (B) in the auricular areas, which normally are not affected in patients with com-
mon acne. Only a few cysts were present on the patient’s back in summer 1998 (C), whereas 1 year later
(D) the patient’s back was covered with many severely inﬂamed cysts. body burden of 0.4 mg and the dose of 6
µg/kg body weight (9). Apart from margin-
ally elevated values of cholesterol and lipase,
an elevated number and percentage of B
lymphocytes, and a decreased percentage of
NK cells, her routine laboratory and
immunologic parameters were within the
normal range. Except for elevated levels of
thyroid-stimulating hormone and prolactin
on single occasions, thyroid and sexual hor-
mones were normal. We treated the patient’s
chloracne with topical tretinoin (Retin A
Cream; Cilag, Schaffhausen, Switzerland),
and within 1 year her skin lesions cleared
almost completely (Figure 2B). She also
completed a trial with olestra (9).
Out of 30 other employees working at
the same institute as these patients, blood
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Table 1. Laboratory results for Patient 1 and Patient 2. 
Patient 1 Patient 2 
Laboratory test Reference value Median Maximum Minimum Median Maximum Minimum
Triglycerides  50–172 mg/dL (0.56–1.9 mmol/L) 287 (7.4) 549 (14.2) 130 (3.4) 113 (2.9) 176 (4.6) 69 (1.8)
Cholesterol 150–200 mg/dL (< 5.2 mmol/L) 228 (5.9) 338 (8.7) 146 (3.8) 201 (5.2) 248 (6.4) 165 (4.3)
a-Amylase total 28–100 U/L 73 149 44 74 80 69
Lipase –60 U/L 39 116 0 77 104 47
CHE 2.8–7.4 kU/L 4.9 6.2 3.4 5.2 6.3 4.0
Alkaline phosphatase  60-170 U/L 140 295 80 91 150 72
GOT (ASAT) –15 U/L 7 11 5 10 12 8
GPT (ALAT) –19 U/L 7 27 2 8 18 5
Gamma-GT 4–18 U/L 16 51 7 11 22 7
LDH 120–240 U/L 147 215 106 121 170 99
Blood count and differential blood counta
Erythrocytes 3.5–5.0 1012/L 3.4 4.2 2.8 4.2 4.5 3.9
Hemoglobin 120–150 G/L 103 138 84 128 142 118
Hematocrit 0.33–0.43 1 0.30 0.37 0.25 0.36 0.41 0.34
Platelet count 150–450 109/L 165 228 74 179 251 141
Leukocytes 3.2–9.8 109/L 18.4 30.6 9.9 8.1 12.2 5.7
Reticulocytes 0.7–2.0% 1.84 2.11 1.41 1.4b ——
Granulocytes 50.0–70.0% 71.6 91 52 59.6 71.4 52.1
Monocytes 0.0–12.0% 5.2 12 1 6.2 7.2 5.5
Lymphocytes 25.0–40.0% 20.5 42 6 31.6 36.8 21.6
CRP –10 mg/L 26 55 5 5 10 < 5
Fibrinogen 1.8–3.9 G/L 4.2 5.4 3.3 2.6 3.9 1.6
Lymphocyte subpopulationsc
T lymphocytes (CD3+) 59–85% 84 88 79 71 73 69
720–2,330/µL 3,648 5,435 2,537 1,750 2,339 1,520
B-lymphocytes (CD19+) 6.4–23% 12.3 17.0 9.0 23.5 26.0 22.0
100–430/µL 537 921 336 579 701 463
T-helper cells (CD3+ CD4+) 31–61% 45 49 41 43 48 41
500–1,760/µL 1,936 2,829 1,289 1,066 1,371 961
T-suppressor cells (CD3+ CD8+) 11–38% 38 41 38 25 26 22
170–1,050/µL 1,668 2,500 1,197 609 797 513
CD4/CD8 ratio 0.9–3.6 1.2 1.5 1.1 1.7 2.1 1.6
Natural killer cells (CD3-CD56/CD16+) 5.6–31% 4.3 6.0 3.0 5.0 8.0 3.0
90–430/µL 182 231 92 121 182 73
Hormonesd
TSH 0.1–4.0 µU/mL 1.5 2.5 0.7 3.8 10.3 2.1
Thyroxine, free 1.0–1.8 ng/dL (12–23 pmol/L) 1.1 (14) 1.4 (18) 0.8 (10) 1.1 (14) 1.3 (21) 0.8 (10)
Androstenedione 0.3–3.10 ng/mL 0.64 0.84 0.48 2.58 2.79 2.33
DHEAS 0.69–3.98 µg/dL 0.18 0.2 0.17 2.69 3.21 2.19
17-OHP F 0.4–1.0 ng/mL; L 1.3–4.3 ng/mL 0.5 0.6 0.4 2.3 (L)  2.6 (L) 2.0 (L)
LH  F 1.5–10 mU/mL; L 0.5–13 mU/mL;  1.8 2.9 1.3 9.3 (L) 15.0 (L) 5.9 (L)
P 14–72 mU/mL
FSH  F 4–13 IU/L; L 2–13 IU/L; P 5–22 IU/L 4.3 5.4 2.3 7.3 (L) 10.0 (L) 5.5 (L)
Prolactin 1.4–24.2 ng/mL 26.6 46.4 12.3 21.6 32.9 10.2
Estradiol F 22–215 pg/mL; L 22–232 pg/mL;  58 87 11 126 (L) 259 (L) 39 (L)
P 191–572 pg/mL
Progesterone  F 0.5–1.0 ng/mL; L 3.0–18.5 ng/mL;  0.20 0.23 0.17 3.96 (L) 11.1 (L) 0.7 (L)
Ov 0.8–2.3 ng/mL
Testosterone 0.06–0.86 ng/mL (0.2–2.9 nmol/L) 0.05 (0.2) 0.06 (0.2) < 0.05 (<0.2) 0.35 (1.2) 0.42 (1.5) 0.17 (0.6)
SBG 19–117 nmol/L  102 117 84 191 199 185
Abbreviations: CHE, cholinesterase; CRP, C-reactive protein; DHEAS, dehydroepiandrosterone; F, follicular phase; FSH, follicle-stimulating hormone; gamma-GT, gamma-glutamyl trans-
ferase; GOT (ASAT), glutamicoxaloacetic-transaminase; GPT (ALAT), glutamic pyruvate transaminase; L, luteal phase; LDH, lactate dehydrogenase; LH, luteinizing hormone; 17-OHP,
17α -hydroxyprogesterone; P, peak; SBG, sex hormone-binding globulin; TSH, thyroid stimulating hormone. Tests were performed from April 1998 to October 2000 for Patient 1 and from
June 1998 to October 2000 for Patient 2, with 3–20 measures/parameter. Routine laboratory tests, T-cell receptor tests, and immunoglobulin rearrangement were performed by the
Clinical Laboratory of the General Hospital, Vienna, Austria; lymphocyte subset analysis was performed at the laboratory of the Division of Immunology and Infectious Diseases,
Department of Dermatology, University of Vienna; bone marrow analysis was performed at the Department of Clinical Pathology and the Department of Internal Medicine, Division of
Hematology, University of Vienna; and karyotype analysis of the blood and stem cells was carried out at the Institute of Medical Biology, University of Vienna. The results of the following
additional laboratory tests were within the normal range and/or negative: bilirubin, high density lipoprotein, low density lipoprotein, very low density lipoproteins, fasting glucose and
oral glucose tolerance test, renal function tests (electrolytes, blood urea nitrogen, creatinine, uric acid), total serum protein and albumin, blood coagulation measures, urinary analysis,
urinary porphyrins, immunoglobulins (IgA, IgG, IgM) including IgG subsets, complement analysis (C3, C4, CH 50), antinuclear antibodies and subsets, and measures of thyroid function
(serum total thyroxine, triiodothyronine, thyroxin-binding globulin, thyroid stimulating test). 
aFemale reference values. bSingle measurement. cReference values (95th percentile; data sheet of the Becton Dickinson Simultest IMK-Lmphocyte assay; Becton-Dickinson, San Jose,
CA). dExcept for thyroid-stimulating hormone and prolactin, only hormone values measured at least 2 months after cessation of hormonal contraceptives were included.analysis for TCDD showed that two men
and one woman had elevated blood levels
(856, 149, and 93 pg/g blood lipids). These
three individuals were asymptomatic. 
To analyze TCDD in blood samples, we
used published methods employing isotope-
labeled internal standards and high resolu-
tion gas chromatography coupled to high
resolution mass spectrometry (ERGO
Forschungsgesellschaft, Hamburg, Germany)
(12,13). These methods were externally
validated in international intercalibration
exercises.
We analyzed initial blood samples for all
2,3,7,8-substituted polychlorinated dibenzo-
p-dioxins (PCDDs) and dibenzofurans
(PCDFs). Other than a slight elevation of
1,2,3,7,8-pentachlorodibenzo-p-dioxin
(1,2,3,7,8-PeCDD; Patient 1, 47.2 pg/g;
Patient 2, 14.5 pg/g blood fat), we detected
no polyhalogenated compounds above back-
ground levels. 
Discussion
At present, despite thorough environmental
and police investigations, the cause of this
unfortunate incident has not been fully
explained. One important reason for this was
the long interval between the presumable
time of intoxication (October 1997) and the
beginning of examinations in spring 1998,
after the diagnosis had been established. The
possibility of a criminal act could not be
excluded, but the respective investigations of
our state attorney were terminated without
success. It is possible that the patients were
exposed to TCDD that was produced, for
example, from 2,4,5-trichlorophenol (TCP),
in the chemical laboratory at the institute
where the patients (who themselves only per-
formed secretarial work) were employed. In
one of the laboratories there was a high con-
centration of TCDD detected in a water
basin and inside the drain. The concurrence
of low-level 1,2,3,7,8-PeCDD, as observed
in our two patients, is a typical pattern in
cases in which TCDD derives from
2,4,5-TCP (14).
Although the route of application could
not be clariﬁed, because of the high TCDD
blood levels, oral ingestion appears to be the
most likely mode of intoxication. Exposures
by other routes of intoxication (through the
skin or by inhalation) are not likely to cause
such high blood levels in two individuals
without strongly contaminating the whole
environment. 
Although this has still not been explained,
it has allowed us the opportunity to follow
the immediate clinical and laboratory course
in patients with high TCDD intoxication.
In humans, the highest reported TCDD lev-
els so far, 10,400 pg/g blood fat in an adult
and 56,000 pg/g blood fat in a child, were
measured in individuals exposed to TCDD
in the Seveso incident (5). 
Chloracne was the most severe health
effect, which led to the diagnosis in Patient
1. Due to this progressive, disfiguring dis-
ease, which is often associated with an
unpleasant odor, her social and marital life
has been significantly affected. Despite
exceedingly high TCDD levels, Patient 2 had
only mild acne; the diagnosis might not have
been established at all if her colleague had not
been diagnosed with chloracne. The mild
manifestation in Patient 2 is also surprising in
light of recent studies which show that chlo-
racne may appear at dioxin blood levels of
approximately 1,000 pg/g blood fat (7,15,16).
Apart from interindividual variation, a possi-
ble explanation for the discrepancy could be
that the preceding data are derived from
investigations in people with predominantly
external exposure. TCDD concentrations in
the skin of these patients presumably
exceeded those observed in patients with
internal intoxication. Because skin exposure
was unlikely in these two patients, our data
might reflect that, in the absence of direct
skin contamination, higher systemic threshold
levels are necessary for chloracne to develop.
Apart from initial lymphocytosis in the
Seveso victims (3,5) and exposure–response
associations of the platelet count in the
BASF workers (4,6), hematologic abnormal-
ities have not been described in other
cohorts with TCDD exposure (7). In the
more severely affected patient (Patient 1), we
observed persistent leukocytosis. This might
be caused by both the extensive inflamma-
tory skin condition and the intermittently
given corticosteroids, rather than being a
direct effect of TCDD. However, we cannot
formally rule out the latter possibility.
Similarly, persistent anemia in this patient
was most likely due to the inﬂammatory skin
condition, although we cannot exclude a
toxic effect on the erythropoiesis by TCDD.
A toxic effect might also explain the initial
thrombopenia in Patient 1.
Because the immune system has been
shown to be a sensitive target of TCDD tox-
icity in animal studies (17), we investigated
immunologic parameters and lymphocyte
subpopulations in our patients. The notable
results included a leukocytosis in Patient 1
and a decreased percentage of NK cells in
both patients. Quantitative and functional
analysis of both the humoral and cellular
arms of the immune system have been unre-
vealing so far. A controlled study on the
immune function is currently under way. 
Slightly elevated blood lipids were still
present after the discontinuation of the
retinoid treatment in Patient 1, indicating
that this could be an effect of TCDD; how-
ever, the steroid intake may also have played
a role in this increase. 
The cause of the amenorrhoea is some-
thing that can only be speculated. TCDD
may have an inhibitory effect on ovulation,
either by a direct effect on ovarian function
[i.e., inhibition of estradiol synthesis
(18,19)] or by induction of cytochrome
P450-mediated metabolism of estradiol (20).
Amenorrhoea may also be caused by hyper-
prolactinemia, which in turn coincided in
our patient with the initiation of Patient 1’s
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Figure 2. Clinical picture of chloracne in Patient 2.
(A) Multiple closed and opened comedones were
conﬁned to the malar region at the time of chlor-
acne diagnosis. (B) After one year of treatment
with topical tretinoin (Retin A cream), the acne
lesions had almost completely cleared.antidepressive therapy with serotonin antag-
onists, which are known to increase pro-
lactin levels (21,22). 
Apart from chloracne and gastrointestinal
symptoms, few clinical symptoms were
observed in these patients in the acute phase
of intoxication. This indicates that compared
to other species, humans are not particularly
sensitive in regard to lethal doses of TCDD;
that is, the applied doses in our patients
highly exceed the median lethal dose (LD50)
of 0.6–2.0 µg/kg body weight in the guinea
pig, the most sensitive species tested (23).
Conclusion
In conclusion and in accordance with the lit-
erature (3–7,13,24,25), we found that our
patients’ chloracne and gastrointestinal
symptoms were associated with TCDD
intoxication, but, even in case of severe poi-
soning, this was not indicated by our routine
laboratory investigation. In Patient 1, the
disfiguring course of chloracne, which was
unresponsive to isotretinoin, was most
impressive, whereas only a mild expression
of chloracne was present in Patient 2 despite
the high TCDD blood level. The varying
clinical findings reported here should alert
physicians that severe TCDD intoxication
may occur in the absence of tangible organ
manifestations or laboratory abnormalities
and that occasionally, in severely intoxicated
patients, only discrete chloracne may be pre-
sent. Long-term follow-up of these patients
is important because the risk of developing
cancer cannot be currently assessed (2,7).
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